Published On: 8/27/2024
ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour
Team members Kathleen Hurwtiz, ScD, Catherine Wiener, and Chase Latour helped author a new Target RWE study presented at ISPE 2024 titled “Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study.”
The study investigates the potential biases in sequential nested trial emulations, a study designed for rare disease research. Using a simulation framework, the authors compared the results of sequential nested trial emulation to those of single-point randomized trials. Watch this research presentation for valuable insights on using sequential nested trial emulations, highlighting the importance of careful study design and analysis to ensure accurate results:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
McKinley Peter
Digital Marketing Specialist
+1 (352) 514-8045
More News
-
12/09/2025
Target RWE Announces Appointment of Alan Brookhart as President of NoviSci at Target RWE -
11/25/2025
Real-World Evidence [RWE] Demonstrates Repatha’s Long-Term Cardiovascular Benefits -
11/04/2025
Target RWE Appoints Sriram Krishnan as New Chief Product Officer -
08/21/2025
Target RWE Presenting at ISPE 2025: Powering Evidence Generation with Causal Inference -
06/24/2025
Target RWE Advances Next-Generation Causal Inference Approaches in Real-World Evidence with New Publications